Primary gastric lymphoma: a review of 45 cases. 1986

A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori

Primary gastric lymphoma accounts for about 2% of gastric neoplasms. The prognosis of patients affected with non-Hodgkin's gastric lymphoma appears better than for other lymphatic sites. In a retrospective study, the authors have analyzed 45 patients, by evaluating the histopathologic characteristics and relative prognostic factors. The main factors significantly influencing 5-yr survival are: serosal penetration (31.17% vs. 71.2%, P less than 0.05), regional lymph node involvement (53.07% vs. 68%), and clinical stage of disease (IE: 85.6%, IVE:10%, P less than 0.001). The histologic characteristics, the high or low grade of malignancy, and patient age can also be considered important prognostic factors, but not statistically significant in our series of cases. Comparison between overall survival and disease-free survival of patients in stages IE and IIE who underwent surgery alone, with those who had chemotherapy and/or radiotherapy after surgery shows a higher survival (85.6%) of the group who had combined treatments, even though this difference is not statistically significant.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
November 1982, Digestive diseases and sciences,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
October 1988, Anales espanoles de pediatria,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
July 1982, Annals of the Royal College of Surgeons of England,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
January 1984, The American journal of gastroenterology,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
January 1991, World journal of surgery,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
January 1987, Folia haematologica (Leipzig, Germany : 1928),
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
January 1995, Minerva chirurgica,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
January 1995, Hepato-gastroenterology,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
September 1994, Revista medica de Chile,
A Ravaioli, and M Amadori, and M Faedi, and G Rosti, and S Folli, and C Barbieri, and G Giorgini, and M Marangolo, and E Emiliani, and D Amadori
May 2008, La Tunisie medicale,
Copied contents to your clipboard!